Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 May;67(5):375-389.
doi: 10.1007/s00011-017-1128-1. Epub 2018 Jan 10.

Evolving notions on immune response in colorectal cancer and their implications for biomarker development

Fabio Grizzi  1 , Gianluca Basso  2 , Elena Monica Borroni  3 , Tommaso Cavalleri  2 , Paolo Bianchi  2 , Sanja Stifter  4 , Maurizio Chiriva-Internati  5 , Alberto Malesci  2   6   3 , Luigi Laghi  2   6   7
Affiliations
Review

Evolving notions on immune response in colorectal cancer and their implications for biomarker development

Fabio Grizzi et al. Inflamm Res. 2018 May.

Abstract

Introduction: Colorectal cancer (CRC) still represents the third most commonly diagnosed type of cancer in men and women worldwide. CRC is acknowledged as a heterogeneous disease that develops through a multi-step sequence of events driven by clonal selections; this observation is sustained by the fact that histologically similar tumors may have completely different outcomes, including a varied response to therapy.

Methods: In "early" and "intermediate" stage of CRC (stages II and III, respectively) there is a compelling need for new biomarkers fit to assess the metastatic potential of their disease, selecting patients with aggressive disease that might benefit from adjuvant and targeted therapies. Therefore, we review the actual notions on immune response in colorectal cancer and their implications for biomarker development.

Results: The recognition of the key role of immune cells in human cancer progression has recently drawn attention on the tumor immune microenvironment, as a source of new indicators of tumor outcome and response to therapy. Thus, beside consolidated histopathological biomarkers, immune endpoints are now emerging as potential biomarkers.

Conclusions: The introduction of immune signatures and cellular and molecular components of the immune system as biomarkers is particularly important considering the increasing use of immune-based cancer therapies as therapeutic strategies for cancer patients.

Keywords: Biomarkers; Chemokines; Colorectal cancer; Immunity; Macrophages; Prognosis; T-lymphocytes.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. N Engl J Med. 2005 Dec 22;353(25):2654-66 - PubMed
    1. Proc Natl Acad Sci U S A. 2010 Apr 13;107(15):6982-7 - PubMed
    1. Int J Cancer. 2015 Mar 1;136(5):E359-86 - PubMed
    1. Lancet. 2008 Mar 1;371(9614):771-83 - PubMed
    1. Cancer. 2016 Mar 15;122(6):929-34 - PubMed

LinkOut - more resources